To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Inclusion Criteria

• •1. Voluntary consent to participate in the study and signed the informed consent form.
• •2. Male or female, age 18-75 years (including both).
• •3. Histologic confirmed non-muscle invasive bladder urothelial carcinoma (NMIBC), and the risk group met the high-risk (including very high-risk) group.
• •Note: High-risk NMIBC is a high-grade / G3 tumor meeting any of the following:
• •a.Carcinoma in situ (CIS) b. T1 stage c. diameter\>3cm d.Multiple tumors, or recurrent tumors.
• •4. Absence of resectable disease（Ta and/or T1 disease） after transurethral resection (TURBT) procedures (residual CIS acceptable;
• •5. The urologist assessed that radical surgery for bladder cancer was not suitable or the subject refused radical surgery for bladder cancer.
• •6. Tumor tissue samples were detected by immunohistochemistry (IHC) to satisfy HER2 expression of 1+, 2+ or 3+.
• •7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• •8. Adequate heart, bone marrow, liver, kidney and coagulation function